Regencell (Nasdaq: RGC) prices $20M registered direct offering
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Regencell Bioscience Holdings Limited has entered a definitive agreement for a registered direct offering of 985,222 ordinary shares at $20.30 per share. The company expects aggregate gross proceeds of about $20.0 million from this primary share sale.
The offering is led by a new fundamental institutional investor committing $19 million, with additional participation from Univest Securities, LLC, which acts as sole placement agent. The transaction is expected to close on or about May 20, 2026, subject to customary closing conditions.
Positive
- None.
Negative
- None.
Insights
Regencell raises $20M through a registered direct share sale.
Regencell Bioscience is issuing 985,222 new ordinary shares at $20.30 each in a registered direct offering, targeting gross proceeds of about $20.0 million. This is a primary capital raise under an effective shelf registration on Form F-3.
The deal is anchored by a new fundamental institutional investor committing $19 million, with Univest Securities, LLC as sole placement agent. Actual impact depends on how the company ultimately deploys the capital and any effects of additional shares on existing holders.
Key Figures
Shares offered: 985,222 shares
Offering price: $20.30 per share
Gross proceeds: $20.0 million
+4 more
7 metrics
Shares offered
985,222 shares
Ordinary shares in registered direct offering
Offering price
$20.30 per share
Purchase price for each ordinary share
Gross proceeds
$20.0 million
Expected aggregate gross proceeds to the company
Lead investor commitment
$19 million
Investment from new fundamental institutional investor
Shelf registration form
Form F-3
File No. 333-294722 for this offering
Par value
$0.00001 per share
Par value of each ordinary share
Expected closing date
On or about May 20, 2026
Planned closing for the offering
Key Terms
registered direct offering, shelf registration statement, Form F-3, prospectus supplement, +1 more
5 terms
registered direct offering financial
"at a purchase price of $20.30 per Ordinary Share in a registered direct offering"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
shelf registration statement regulatory
"The offering is being made pursuant to a shelf registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
Form F-3 regulatory
"shelf registration statement on Form F-3 (File No. 333-294722)"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
prospectus supplement regulatory
"A prospectus supplement (File No. 333-294722) and accompanying prospectus describing the terms"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Offering Details
secondary
Offering
Offering Type
secondary
Price Range
$20.30 per share
FAQ
What did Regencell Bioscience (RGC) announce in this 6-K filing?
Regencell Bioscience announced a registered direct offering of 985,222 ordinary shares at $20.30 per share. The company expects to raise approximately $20.0 million in gross proceeds from this primary equity issuance.
How much capital will Regencell Bioscience (RGC) raise in the offering?
Regencell Bioscience expects aggregate gross proceeds of about $20.0 million from the offering. This comes from selling 985,222 ordinary shares at a purchase price of $20.30 per share to participating investors.
Who is leading Regencell Bioscience’s new registered direct offering?
The offering is led by a new fundamental institutional investor committing $19 million. Univest Securities, LLC is also participating and is acting as the sole placement agent for this registered direct share sale.
Under which SEC registration has Regencell Bioscience structured this offering?
The offering is being conducted under an effective shelf registration statement on Form F-3 (File No. 333-294722). A prospectus supplement and accompanying prospectus describing the terms are being filed with the SEC.
What type of securities is Regencell Bioscience (RGC) selling in this transaction?
Regencell Bioscience is selling ordinary shares, each with a par value of $0.00001. The company will issue an aggregate of 985,222 of these ordinary shares in the registered direct offering described.